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commentary
Building bridges: PCSK7 as a NAFLD candidate
gene connecting hepatic inflammation with
hypertriglyceridemia1
Rotonya M. Carr, Junior Associate Editor,2,* and Nicholas O. Davidson, Editor-in-Chief 2,†
Division of Gastroenterology, *Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104;
and Gastroenterology Division,† Department of Medicine, Washington University School of Medicine, Saint
Louis, MO 63110

enrolled after liver biopsy confirmed NASH diagnosis; 2)
the UK Biobank (UKBBC), a genetic dataset of UK participants; and 3) the Dallas Heart Study (DHS), a US-based,
multi-ethnic cohort of participants who reside in Dallas
County, Texas. The effect of the PCSK7 rs236918 C risk
variant on liver injury was estimated by measuring the association of the variant with either histologic or surrogate
markers of steatosis, hepatic inflammation, and fibrosis in
the three cohorts. In the LBC, there was an association
between the PCSK7 rs236918 C risk allele, abnormal hepatic transaminases, and histologic lobular inflammation,
although not with the sine qua non NASH histologic findings of hepatocellular ballooning or fibrosis. Perhaps
counterintuitively, there was no association with steatosis
in either the LBC or DHS cohorts except in LBC subjects
considered high risk for progressive NAFLD or who carried the previously validated NASH genetic risk allele
I148M PNPLA3 variant. Phenotypically, the PCSK7 risk
variant associated with liver failure and cirrhosis in the
UKBBC dataset; however, there was no stratification by
PNPLA3 status in this cohort.
Dongiovanni et al. convincingly demonstrate that PCSK7
expression contributes to the TG phenotype, showing a
positive association of the rs236918 C risk variant with hypertriglyceridemia in the LKB dataset. In addition, they
observed an association of another low-frequency missense mutation in PCSK7 (rs142953140) with elevated circulating TGs in the DHS cohort and association of a
low-frequency PCSK7 missense mutation (rs142953140)
found in African Americans with lower TGs. Finally, in the
UKBB, the PCSK7 risk variant was associated with cardiovascular disease and hypercholesterolemia, perhaps reflecting the previously established relationship between
hypertriglyceridemia and propensity for development of
atherogenic, lower density LDL particles (9).
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Nonalcoholic fatty liver disease (NAFLD) now ranks as
the most prevalent liver disease worldwide (1), but progression from its more indolent stage of nonalcoholic fatty liver
(NAFL) to advanced stages of nonalcoholic steatohepatitis
(NASH) is not well understood. The accumulation of neutral lipids (principally triglycerides, TGs) within hepatocellular lipid droplets (LDs) in obese subjects with NAFL
largely reflects increased de novo lipogenesis. In addition,
the excessive hepatic TG burden also promotes augmented
VLDL secretion and leads to systemic hypertriglyceridemia.
The progressive forms of liver injury with NASH are characterized by lipotoxicity, hepatic inflammation, and fibrosis,
but the mechanisms linking alterations in circulating triglycerides and LD turnover to NASH remain obscure.
In this issue of the Journal of Lipid Research, Dongiovanni
et al. propose that upregulation of the type I membranebound pro-protein convertase subtilisin/kexin type 7
(PCSK7) mechanistically links hypertriglyceridemia with
hepatic inflammation via hepatic iron dysmetabolism. Discovered in 1996 as one of nine secretory pro-protein convertase family members responsible for the intracellular
cleavage of pro-proteins, PCSK7 is a relatively conserved
protein with nearly ubiquitous tissue distribution (2). Genome-wide association study data have demonstrated an
association between the PCSK7 rs236918 C risk allele, soluble transferrin receptor (3), liver cirrhosis in hemochromatosis patients (4), and hypertriglyceridemia (5, 6).
Because of these prior genetic associations and evidence
that excessive hepatic iron accumulation predicts hepatic
inflammation and fibrosis in NASH (7, 8), Dongiovanni
et al. hypothesized that PCSK7 may be “the bridge that
connects lipid dysregulation with liver injury in NAFLD”.
The investigators used three genetic cohorts to explore
the relationship between the PCSK7 rs236918 C risk allele,
iron dysmetabolism, liver injury, and hypertriglyceridemia:
1) the Liver Biopsy Cohort (LBC), a group of European
adults from Italian and Finnish referral centers who were
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modulates these pathways. One possibility, given the ubiquitous distribution of PCSK7, could include the role of altered intestinal chylomicron assembly and secretion. The
emergence of genetically modified in vivo models would
enable these physiologic questions to be answered. Nevertheless, Dongiovanni and colleagues have established an
approach to move beyond genome-wide association study
data to more mechanistic underpinnings of NASH development and provide strong evidence that PCSK7 should
be added to the growing list of genetic modifiers at the
interface of NAFL and NASH phenotypes (11).
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Using a combination of bioinformatics and gene transcript expression data, the authors propose that the PCSK7
risk variant is a gain-of-function mutation that increases
hepatic PCSK7 protein expression (and secretion) by modulating expression of an 83 bp regulatory segment of long
noncoding RNA (so-called “intra-PCSK7” lnc RNA). In support of this hypothesis, they observed increased hepatic
expression of intra-PCSK7 in severely obese (a NAFLDenriched population) carriers of the PCSK7 rs236918 C
allele. Moreover, both hepatic and circulating PCSK7 protein expression were increased in risk allele carriers, the
latter of which correlated positively with circulating TG
levels in NAFLD patients.
A mechanistic examination of the authors’ hypothesis
in PCSK7 haploinsufficient HepG2 cells revealed impaired
PCSK7 secretion, a relative reduction in the de novo lipogenic genes FAS and SREBP1, and reduced FA-induced
neutral lipid accumulation compared with wild-type
HepG2 cells. Haploinsufficiency also resulted in the downregulation of the inflammatory gene TNFa and of the fibrogenic gene TGFb and its downstream effectors SMAD2/3
and SMAD4.
Although the in vitro data are bolstered by the finding
in severely obese patients that hepatic PCSK7 expression
correlates with FAS, TGFb, actin, and Col1A1 gene expression, the authors’ transcriptome pathway analysis adds a
level of complexity to the biology of PCSK7. Specifically,
they demonstrate coexpression of PCSK7 with genes involved in inflammation, epithelial mesenchymal transition, and mitosis but unlike the in vitro data, they found
an inverse correlation with pathways involved in adipogenesis and FA metabolism. Those findings imply that the effects of PCSK7 on FA utilization may either be in promoting
oxidation (as evidenced by the positive correlation with
the b oxidative genes PPARa and CPT1 in HepG2 PCSK7
haploinsufficient cells and severely obese subjects) or in
downregulating b oxidation as demonstrated by the inverse correlation of PCSK7 with oxidative phosphorylation
pathways in transcriptome analysis. Understanding the
relationship of PCSK7 with hepatic fat oxidation is critical
as strategies that target PCSK7 could either improve or
worsen the NAFLD phenotype.
Dongiovanni et al. have built a few more beams to “span
the tide” (10) in NAFLD pathogenesis. What remains is to
define in greater detail the link between dysregulated hepatocellular LD formation and turnover and systemic hypertriglyceridemia and the mechanisms by which PCSK7

